CD8A and neoplasm: Furthermore, they also demonstrated that the Hsp70-engineered exosomes from these MM cells could be used as a tumor vaccine to induce the maturation of DC and trigger the activation of NK cells, CD4 + Th1, and P1A-specific CD8+CTL, hence resulting in a more potent anti-tumor immunity [132].